Nwm 25 March 2015 Programme & Biogs

Biosimilars – a Protein-Engineered Biotech Trend for the Future?

25 March 2015

Cambridge Airport, Cambridge

Programme 16.15

16.45

Registration Welcome from the Host and Chair

17.00 Minimising Therapeutic Antibody Immunogenicity Dr Matthew Baker, CSO, Abzena 17.30 Commercial Considerations for Biosimilar Developers Sahar Shepperd, Associate, Bristows LLP 17.40 Impact of Patent Law on Biosimilars Dominic Adair, Partner, Bristows LLP 18.00

Refreshments and Tour of Terminal

18.30 Q&A Discussion: What Does the Rise of Biosimilars Mean for the Biotech Industry?

19.30

Closing Remarks from the Chair

19.35

Networking, Drinks and Canapes

20.30

Event closes

Speaker Profiles Dominic Adair, Partner, Bristows LLP Title: Impact of Patent Law on Biosimilars

Dominic is a partner at Bristows LLP, specialising in patent litigation. His practice focuses on the life sciences, reflecting his technical background (PhD Zoology, University of Cambridge).

Dominic has extensive experience of cross-border litigation in and beyond Europe and has worked on all aspects of the pharmaceutical product life cycle, from freedom to operate analyses and early-stage risk assessment of generic competition to end-stage litigation, SPCs and anti-trust issues.

Dominic writes regularly on reported patent cases in the UK and at the EPO and is a member of the AIPPI. He is a regular conference speaker and presenter.

Matthew Baker, CSO, Abzena Plc Title: Minimising Therapeutic Antibody Immunogenicity Dr Baker completed a PhD in cellular immunology at University of Birmingham UK and after completing postdoctoral positions in Cambridge moved into the biotechnology industry where he has held senior management positions at a number of companies including Biovation (subsidiary of Merck KGaA), Cellular Technologies Limited and Whatman BioSciences. Dr Baker is the Chief Scientific Officer of Abzena (part of the PolyTherics group) in Cambridge, UK.

Sahar Shepperd, Associate, Bristows LLP Title: Commercial Considerations for Biosimilar Developers Sahar is an Associate in the IP and commercial transactions department. Prior to joining Bristows, Sahar gained several years of experience in house at Cambridge Antibody Technology (part of the AstraZeneca Group) where she trained and qualified as a Solicitor.

Sahar has broad IP experience (both contentious and non-contentious) and advises clients on a range of transactional matters, including technology and product licenses, intellectual property agreements, settlement agreements, clinical trial agreements and research and development agreements.

Matters that Sahar has recently advised on include: - assisting Genomics England in securing the services of Illumina with respect to the 100,000 genome project, the largest of its kind to date; - assisting Locate Therapeutics in securing funding from Heraeus Holdings and subsequently entering into a licence agreement with Heraeus Medical; - assisting Ariosa Diagnostics in its agreement with UK clinical laboratories; - In-license and purchase of clinical assets in the biotechnology sector; and - setting up multi-site, multi-jurisdictional clinical trials.

- Sahar is also a member of the BIA IPAC Committee.

Given her strong scientific background and detailed knowledge of the life sciences sector, Sahar has the expertise necessary to understand both the commercial and technical aspects of intellectual property matters.

Delegate List Surname Adair Bach Baker Bentham Birrell Blakemore Browne Butt Carridge Cohen Dancer Deal Deal Gillespie Hancock Hill Januszewski Jones Jones Kanabar Keen Lallement McGhee Mercer Michael Murrall Ness Nir Nir Noble Obrezanova Postle Roberts Roberts Shaw Shepperd Shivji Spencer Velamakanni Wakes Weston-Smith

First name Dominic Peter Matthew Andy Graham James Ken Neil Andrew Helen Jane Greer Bobby Dee Chris Guy Tadeusz Phil Tony Pradyp Simon Arthur Alison Elizabeth (Liz) Adam Nicholas Sam Dror Rina Nick Olga Martyn Michael Dave Daniel Sahar Nadia Matthew Saroj Nicole Miranda

Company Bristows LLP BioPharmaLogic LLC Abzena PLC J A Kemp OCT Cambridge Consultants SELECTBIO Abzena PLC Reddie & Grose LLP HC Pharma Consultancy Limited F-star Biotechnology Ltd Global Regulatory Services Global Regulatory Services Consultant George James Ltd Preome Ltd MedImmune Limited F-star Biotechnology Ltd One Nucleus Bio-Analytical Technologies (UK) Limited Abzena PLC Retroscreen Virology Ltd F-star Biotechnology Ltd Perla Development Ltd 80th Atom Consultant - Nick Murrall Department of Chemistry, University of Cambridge RadBee Ltd RadBee Ltd Tepnel Pharma Services Lonza Biologics Plc Cambridge Healthcare and Biotech Ltd Reddie & Grose LLP Selcia Limited Reddie & Grose LLP Bristows LLP One Nucleus Boult Wade Tennant Fahy Gurteen Laboratories Abzena PLC Consultant